Tags

Type your tag names separated by a space and hit enter

Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Pathology. 2018 Dec; 50(7):748-752.P

Abstract

Pseudomonas aeruginosa is a common pathogen causing nosocomial infection. In particular, bloodstream infection (BSI) is associated with a high rate of morbidity and mortality. Ceftolozane/tazobactam is a new β-lactam/β-lactamase antimicrobial with activity against P. aeruginosa as well as multidrug resistant (MDR) Gram negative Enterobacteriaceae. Ceftolozane/tazobactam has frequently been used in salvage therapy for MDR P. aeruginosa infections. The aim of this study was to determine the activity of ceftolozane/tazobactam against P. aeruginosa isolates from BSIs collected from three clinical microbiology laboratories in Queensland, Australia, with a high proportion of isolates demonstrating β-lactam resistance. Antimicrobial susceptibility testing was performed by broth microdilution using custom made sensititre plates sourced from ThermoFisher Scientific. In addition to ceftolozane/tazobactam, we also tested piperacillin/tazobactam, ceftazidime, cefepime, meropenem, doripenem, imipenem, aztreonam, ciprofloxacin, levofloxacin, gentamicin, amikacin, tobramycin and colistin. Overall, ceftolozane/tazobactam was the most active agent tested [(MIC50/90 = 1/2 μg/mL, 96% susceptible (S)]. Against 44 isolates with resistance to at least one other β-lactam agent, 40 were susceptible to ceftolozane/tazobactam. Three ceftolozane/tazobactam resistant isolates were susceptible to colistin, with one of those isolates also susceptible to levofloxacin but not to any other antimicrobials tested. One ceftolozane/tazobactam resistant isolate was susceptible only to meropenem and doripenem but was non-susceptible to imipenem. An association was found between fluoroquinolone resistance and aminoglycoside resistance but not with β-lactam resistance. In summary, ceftolozane/tazobactam was active against most strains tested, including those resistant to other β-lactams. Laboratories should consider testing P. aeruginosa against ceftolozane/tazobactam in suspected MDR or extensively drug resistant (XDR) infections.

Authors+Show Affiliations

UQ Centre for Clinical Research, The University of Queensland, Brisbane, Qld, Australia; Infection Management Services, Princess Alexandra Hospital, Brisbane, Qld, Australia. Electronic address: andrew@hendonet.com.UQ Centre for Clinical Research, The University of Queensland, Brisbane, Qld, Australia.UQ Centre for Clinical Research, The University of Queensland, Brisbane, Qld, Australia.UQ Centre for Clinical Research, The University of Queensland, Brisbane, Qld, Australia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30392710

Citation

Henderson, A, et al. "Activity of Ceftolozane/tazobactam Against a Collection of Pseudomonas Aeruginosa Isolates From Bloodstream Infections in Australia." Pathology, vol. 50, no. 7, 2018, pp. 748-752.
Henderson A, Tan E, McCarthy KL, et al. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia. Pathology. 2018;50(7):748-752.
Henderson, A., Tan, E., McCarthy, K. L., & Paterson, D. L. (2018). Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia. Pathology, 50(7), 748-752. https://doi.org/10.1016/j.pathol.2018.08.009
Henderson A, et al. Activity of Ceftolozane/tazobactam Against a Collection of Pseudomonas Aeruginosa Isolates From Bloodstream Infections in Australia. Pathology. 2018;50(7):748-752. PubMed PMID: 30392710.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia. AU - Henderson,A, AU - Tan,E, AU - McCarthy,K L, AU - Paterson,D L, Y1 - 2018/11/02/ PY - 2018/05/27/received PY - 2018/07/31/revised PY - 2018/08/07/accepted PY - 2018/11/6/pubmed PY - 2019/1/16/medline PY - 2018/11/6/entrez KW - Ceftolozane/tazobactam KW - Pseudomonas aeruginosa KW - antimicrobial susceptibility testing SP - 748 EP - 752 JF - Pathology JO - Pathology VL - 50 IS - 7 N2 - Pseudomonas aeruginosa is a common pathogen causing nosocomial infection. In particular, bloodstream infection (BSI) is associated with a high rate of morbidity and mortality. Ceftolozane/tazobactam is a new β-lactam/β-lactamase antimicrobial with activity against P. aeruginosa as well as multidrug resistant (MDR) Gram negative Enterobacteriaceae. Ceftolozane/tazobactam has frequently been used in salvage therapy for MDR P. aeruginosa infections. The aim of this study was to determine the activity of ceftolozane/tazobactam against P. aeruginosa isolates from BSIs collected from three clinical microbiology laboratories in Queensland, Australia, with a high proportion of isolates demonstrating β-lactam resistance. Antimicrobial susceptibility testing was performed by broth microdilution using custom made sensititre plates sourced from ThermoFisher Scientific. In addition to ceftolozane/tazobactam, we also tested piperacillin/tazobactam, ceftazidime, cefepime, meropenem, doripenem, imipenem, aztreonam, ciprofloxacin, levofloxacin, gentamicin, amikacin, tobramycin and colistin. Overall, ceftolozane/tazobactam was the most active agent tested [(MIC50/90 = 1/2 μg/mL, 96% susceptible (S)]. Against 44 isolates with resistance to at least one other β-lactam agent, 40 were susceptible to ceftolozane/tazobactam. Three ceftolozane/tazobactam resistant isolates were susceptible to colistin, with one of those isolates also susceptible to levofloxacin but not to any other antimicrobials tested. One ceftolozane/tazobactam resistant isolate was susceptible only to meropenem and doripenem but was non-susceptible to imipenem. An association was found between fluoroquinolone resistance and aminoglycoside resistance but not with β-lactam resistance. In summary, ceftolozane/tazobactam was active against most strains tested, including those resistant to other β-lactams. Laboratories should consider testing P. aeruginosa against ceftolozane/tazobactam in suspected MDR or extensively drug resistant (XDR) infections. SN - 1465-3931 UR - https://www.unboundmedicine.com/medline/citation/30392710/Activity_of_ceftolozane/tazobactam_against_a_collection_of_Pseudomonas_aeruginosa_isolates_from_bloodstream_infections_in_Australia_ DB - PRIME DP - Unbound Medicine ER -